# US 2016/0258019 A1 · Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0258019 A1
- Document ID: US20160258019A1
- Status: Published application
- Kind: A1
- Application number: 15/028,732
- Filed: 2014-10-14
- Published: 2016-09-08
- Earliest claimed: 2013-10-13
- Assignees: The Research Foundation for the State University of Newyork
- Applicants: The Research Foundation for Suny
- Inventors: Alison E. BAIRD; Mateusz ADAMSKI
- Web page: https://patentgrep.com/patent/US20160258019A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6851: Quantitative amplification
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Biomarkers useful for the diagnosis and treatment of acute ischemic stroke are disclosed. Also provided is a quantitative assay method for accurately identifying transcript number in a biological sample.

## Claims

### Claim 1

A method for identifying patients having an increased risk for acute ischemic stroke, comprising:
a) obtaining a biological sample from said patient,
b) determining the expression levels of at least three genes from Table 4, wherein upregulation of said markers relative to predetermined control levels observed in non-afflicted controls, are indicative of an increased risk for the development of acute ischemic stroke.

### Claim 2 (depends on 1)

The method of claim 1, wherein said three genes are PLBD1, PYGL2, and BST1.

### Claim 3 (depends on 2)

The method of claim 2, further comprising analysis of DUSP1, VCAN, FCGR1A and FOS.

### Claim 4 (depends on 2)

The method of claim 2, further comprising analysis of DUSP1, FOS, NPL, KIAA0146 and ENTPD1.

### Claim 5 (depends on 1)

The method of claim 1, wherein said genes consist of PILRA, BCL6, FPR1, LY96, S100A9, S100A12 and MMP9.

### Claim 6 (depends on 1)

The method of claim 1, further comprising determination of expression levels of any of the markers listed in Table 4.

### Claim 7 (depends on 1)

The method of claim 1, comprising determination of expression levels of each of BST1, S100A9, PLBD1, S100A12, SUSP1, ETS2, S100P, FOS, CYBB, PYGL, F5, CD93, ENTPD1, CKAP4, ADM and IQGAP1.

### Claim 8 (depends on 1)

The method of claim 1, comprising determination of expression levels of each of PLBD1, PYGL2, BST1, DUSP1, VCAN, FCGR1A and FOS.

### Claim 9 (depends on 1)

The method of claim 1, wherein the predetermined levels are mean expression levels across the patient cohort.

### Claim 10 (depends on 1)

The method of claim 1 wherein said determining step comprises contacting said sample with an agent having affinity for said ischemic stroke associated markers, said agent forming a specific binding pair with said markers and further comprising a detectable label, measuring said detectable label, thereby determining expression level of said marker in said sample.

### Claim 11 (depends on 1)

The method of claim 1, wherein said expression levels are determined using an input quantity method.

### Claim 12 (depends on 1)

The method of claim 1 wherein said markers are selected from the group consisting of polypeptides, nucleic acids or fragments thereof.

### Claim 13 (depends on 1)

The method as claimed in claim 1, wherein said molecules comprise polypeptides or fragments thereof, said agent is an antibody or fragment thereof and said polypeptide is detected by a method selected from the group consisting of flow cytometric analysis, immunohisto-chemical detection and immunoblot analysis.

### Claim 14 (depends on 1)

The method as claimed in claim 1 wherein said molecules comprise nucleic acids or fragments thereof, said agent is complementary nucleic acids which hybridizes to said molecules and said ischemic stroke associated nucleic acid is detected by a method selected from the group consisting of in situ hybridization assay, hybridization assay, gel electrophoresis, RT-PCR, real time PCR, and microarray analysis.

### Claim 15 (depends on 1)

The method as claimed in claim 1, wherein said biological sample is a peripheral blood sample.

### Claim 16 (depends on 1)

The method of claim 1, further comprising creating a report summarizing the data obtained by the determination of said ischemic stroke associated marker expression levels.

### Claim 17 (depends on 16)

The method of claim 16, wherein said report includes recommendation for a treatment modality of said patient.

### Claim 18 (depends on 1)

The method of claim 1, wherein said patient is diagnosed with acute ischemic stroke and is undergoing treatment for said stroke.

### Claim 19 (depends on 1)

A kit for practicing the method of claim 1.

### Claim 20

A method for identifying agents which useful for the treatment of acute ischemic stroke, comprising:
a) contacting a cell comprising one or more ischemic stroke associated markers from Table 4 with a test agent; and
b) assessing the effect of said agent on modulation of expression levels of said markers relative to untreated cells, agents which modulate expression of any of the markers in step a) having utility for the treatment of acute ischemic stroke.

### Claim 21 (depends on 8)

A method for assessing an increased risk for the development acute ischemic stroke in a human patient and administering treatment for ameliorating symptoms of said stroke if necessary to said patient, comprising:
a) obtaining a peripheral blood sample from said patient;
b) determining the expression levels of ischemic stroke associated markers of claim 8, wherein upregulation of said markers relative to predetermined control levels observed in stroke afflicted subjects are indicative of an increased risk for the development of acute ischemic stroke; and
c) administering an agent useful for the amelioration of stroke symptoms to said patient.

### Claim 22 (depends on 20)

A kit for practicing the method of claim 20.

### Claim 23

A method for quantitative analysis of standard and high-throughput qPCR expression data based on input sample quantity, comprising
a) obtaining a biological sample for analysis of target gene expression from a test subject and a control subject;
b) measuring input quantity of said samples and extracting RNA transcripts;
c) reverse transcribing said extracted RNA transcripts into cDNA and amplifying said cDNA via polymerase chain reaction;
d) determining amplification efficiency and correlation coefficients for each amplified transcript, wherein relative fold changes between said test and control are calculated using
T
C
C
C
=
ccC
ccT
×
(
1
+
E
)
(
nCq
,
C
-
nCq
,
T
)
wherein, when cells are used as the biological sample, Tc is the number of transcripts per cell in said test subject, Cc is the number of transcripts per cell in a control subject, ccT is the input cell count for said test subject, ccC is the cell input for said control subject, E is the efficiency of target cDNA amplification, and nCq is the cycle number at which amplification crosses the threshold.

### Claim 24 (depends on 23)

The method of claim 23 wherein absolute value differences between target gene transcripts in test subject and control subject are determined, wherein efficiency of target cDNA amplification is known and said method further comprises introduction of a standard reference sample containing a known quantity of said transcripts, said absolute value difference being calculated using
X
C
=
(
1
+
E
)
(
nCq
,
cDNA
-
nCq
,
X
)
ccX
.

### Claim 25 (depends on 23)

The method of claim 23 wherein absolute value differences between target gene transcripts in test subject and control subject are determined, wherein efficiency of target cDNA amplification is unknown and said method further comprises introduction of a standard reference sample containing a known quantity of said transcripts, said absolute value difference being calculated using
X
C
=
2
(
nCq
,
cDNA
-
nCq
,
X
)
ccX


X
C
=
2
(
nCq
,
cDNA
-
nCq
,
X
)
ccX
.
[
15
]

### Claim 26 (depends on 23)

The method of claim 23, wherein said sample contains cells in solution and input sample quantity is measured as cell count.

### Claim 27 (depends on 23)

The method of claim 23, wherein said sample is a tissue sample and input sample quantity is measured as tissue volume.

### Claim 28 (depends on 23)

The method of claim 23, wherein said sample is a tissue sample and input sample quantity is measured as tissue weight.
